BioTuesdays
IceCure
Markets

AGP starts IceCure Medical at buy; PT $14.50

Alliance Global Partners launched coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $14.50. The stock closed at $8.61 on Sept. 21. IceCure has developed and markets the IceCure family of...

September 22, 2021
Dermata Therapeutics Logo
Markets

Brookline starts Dermata Therapeutics at buy; PT $14

Brookline Capital Markets initiated coverage of Dermata Therapeutics (NASDAQ:DRMA) with a “buy” rating and a price target of $14. The stock closed at $4.87 on Sept. 20. Dermata is developing DMT310, a once-weekly...

September 21, 2021
Pennant Group logo
Markets

Stifel starts Pennant Group at buy; PT $37

Stifel launched coverage of Pennant Group (NASDAQ:PNTG) with a “buy” rating and price target of $37. The stock closed at $29.88 on Sept. 20. “We believe home health and hospice are the fastest-growing areas of...

September 20, 2021
Clarus-Therapeutics
Markets

Cantor starts Clarus Therapeutics at OW; PT $20

Cantor Fitzgerald initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with an “overweight” rating and $20 price target. The stock closed at $8.81 on Sept. 17. Clarus is focused on developing androgen and metabolic...

September 20, 2021
Equillium
Markets

Cantor starts Equillium at OW, PT $14

Cantor Fitzgerald launched coverage of Equillium (NASADQ:EQ) with an “overweight” rating and $14 price target. The stock closed at $5.40 on Sept. 14. Equillium is developing itolizumab, its novel CD6 targeted monoclonal...

September 15, 2021
Sonnet-BioTherapeutics
Markets

BTIG starts Sonnet BioTherapeutics at buy; PT $5

BTIG launched coverage of Sonnet BioTherapeutics (NASDAQ:SONN) with a “buy” rating and price target of $5. The stock closed at 56 cents on Sept. 14. Sonnet is an early-stage biotechnology company working to develop...

September 15, 2021
180-Life-Sciences
Markets

Maxim starts 180 Life Sciences at buy; PT $11

Maxim Group initiated coverage of 180 Life Sciences (NASDAQ:ATNF) with a “buy” rating and $11 price target. The stock closed at $5.67 on Sept. 14. 180 Life Sciences is developing anti-inflammatory products with three...

September 15, 2021
Aadi-Bioscience
Markets

Ladenburg starts Aadi Bioscience at buy; PT $51

Ladenburg Thalmann launched coverage of Aadi Bioscience (NASDAQ:AADI) with a “buy” rating and price target of $51. The stock closed at $27.96 on Sept. 13. Aadi is a clinical-stage biotechnology company with a single...

September 14, 2021
Assembly Biosciences
Markets

HCW starts Assembly Biosciences at neutral; PT $3.50

H.C.Wainwright initiated coverage of Assembly Biosciences (NASDAQ:ASMB) with a “neutral” rating and price target of $3.50. The stock closed at $3.23 on Sept. 10. Assembly is focused on developing treatments for chronic...

September 13, 2021
Effector-Therapeutics
Markets

Cantor starts eFFECTOR Therapeutics at OW; PT $50

Cantor Fitzgerald launched coverage of eFFECTOR Therapeutics (NASDAQ:EFTR) with an “overweight” rating and price target of $50. The stock closed at $26.59 on Sept. 10. eFFECTOR is focused on developing a new class of...

September 13, 2021
ContraFect Logo
Markets

SVB Leerink starts ContraFect at OP; PT $14

SVB Leerink initiated coverage of ContraFect (NASDAQ:CFRX) with an “outperform” rating and sum-of-the-parts price target of $14. The stock closed at $3.90 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that...

September 9, 2021
Aligos-Therapeutics
Markets

SVB Leerink starts Aligos Therapeutics at OP; PT $29

SVB Leerink initiated coverage of Aligos Therapeutics (NASDAQ:ALGS) with an “outperform” rating and $29 price target. The stock closed at $15.31 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that Aligos is unique among...

September 9, 2021
scPharmaceuticals
Markets

SVB Leerink starts scPharmaceuticals at MP; PT $6

SVB Leerink launched coverage of scPharmaceuticals (NASDAQ:SCPH) with a “market perform” rating sum-of-the-parts PT of $6. The stock closed at $5.95 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that, among other...

September 9, 2021
Greenlane
Markets

AGP starts Greenlane at buy; PT $6

Alliance Global Partners initiated coverage of Greenlane Holdings (NASDAQ:GNLN) with a “buy” rating and $6 price target. The stock closed at $2.73 on Sept. 3. Analyst Aaron Grey writes that Greenlane is now positioned...

September 7, 2021
Eliem-Therapeutics
Markets

Stifel starts Eliem Therapeutics at buy; PT $35

Stifel launched coverage of Eliem Therapeutics (NASDAQ:ELYM) with a “buy” rating and price target of $35. The stock closed at $27.56 on Sept. 3. Eliem is a clinical-stage biotechnology company focused on developing...

September 7, 2021
Surrozen
Markets

Stifel starts Surrozen at buy; PT $19

Stifel launched coverage of Surrozen (NASDAQ:SRZN) with a “buy” rating and $19 target price. The stock closed at $7.24 on Sept. 3. Surrozen discovers and develops biologic drug candidates to selectively modulate the Wnt...

September 7, 2021
Assembly Biosciences
Markets

WB cuts Assembly Biosciences to MP from OP

William Blair downgraded Assembly Biosciences (NASDAQ:ASMB) to “market perform” from “outperform” after the company discontinued clinical development of ABI-H2158, its second-generation core inhibitor for the treatment...

September 2, 2021
Talis-Logo
Markets

BTIG cuts Talis Biomedical to neutral without PT

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “neutral” from “buy” and removed its price target after president, CEO, director and co-founder, Brian Coe, stepped down from the board and executive. The stock closed...

September 1, 2021
Palisade-Bio
Markets

Maxim starts Palisade Bio at buy; PT $7

Maxim Group initiated coverage of Palisade Bio (NASDAQ:PALI) with a “buy” rating and price target of $7. The stock closed at $2.73 on Aug. 30. Palisade Bio is a clinical-stage company developing LB1148, an oral...

August 31, 2021